Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05646485 · ClinicalTrials.gov registry record · NA
Bladder Cancer Screening Trial
A NA study of Smoking Cessation and Bladder Cancer, sponsored by University of Texas Southwestern Medical Center.
- Recruiting
- Registry status
- NA
- Development phase
- 1,000
- Enrollment target
- 1
- Study location
NCT05646485: Recruiting NA study of Smoking Cessation and Bladder Cancer, sponsored by University of Texas Southwestern Medical Center.
NCT05646485 is a NA study of Smoking Cessation and Bladder Cancer that is actively recruiting participants, run by University of Texas Southwestern Medical Center. The registered enrollment target is 1,000 participants, above the 469-participant average among 188 other Smoking Cessation trials with a reported enrollment target (113% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05646485, a NA study of Smoking Cessation and Bladder Cancer, is actively recruiting participants, sponsored by University of Texas Southwestern Medical Center.
- RECRUITING
- Registry status
- NA
- Development phase
- 1,000 participants
- Enrollment target
- 1
- Study location
Study Summary
There is currently no accepted screening strategy for patients at high risk of developing bladder cancer. This study will ask patients to complete a urine test every 6 months for 2 years to help assess if routine screening helps finding bladder cancer at an earlier stage.
Primary Outcome
Incidence of Bladder cancer is measured by the number of participants who were detected with BCa.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Urinalysis
Study Locations (1)
Texas
- University of Texas Southwestern Medical Center - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,000 participants |
| Start Date | 2023-05-05 |
| Est. Completion | 2028-04 |
| Phase | NA |
What NCT05646485 shows while recruiting
NCT05646485 is an interventional study that assigns participants to a tested intervention. Its 1,000 participants enrollment target places it among the larger protocols in the corpus, above the 469-participant average among 188 other Smoking Cessation trials with a reported enrollment target (113% higher).
The record links to 4 conditions, with Smoking Cessation appearing as the primary indexed condition, and to 1 intervention - of which Urinalysis is the first listed.
NCT05646485 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT05646485 about?
NCT05646485 is a clinical study titled "Bladder Cancer Screening Trial". There is currently no accepted screening strategy for patients at high risk of developing bladder cancer. This study will ask patients to complete a urine test every 6 months for 2 years to help assess if routine screening helps finding bladder cancer at an earlier stage.
What is the current status of trial NCT05646485?
This trial is currently recruiting. It is a NA study. The enrollment target is 1,000 participants. The study started on 2023-05-05. Estimated completion is 2028-04.
What conditions does trial NCT05646485 study?
This clinical trial studies the following conditions: Smoking Cessation, Bladder Cancer, Urothelial Carcinoma, Hematuria.
What interventions are being tested in trial NCT05646485?
The interventions under investigation include: Urinalysis (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT05646485?
This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05646485 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Smoking Cessation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05646485's enrollment target sits among peer trials
1,000 23rd of 188 higher than 166 of 188 other Smoking Cessation trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Smoking Cessation trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Clinical Research Evaluating Smoking Cessation With E-Cigarettes and Nicotine Therapy
RECRUITING · NA
-
Scalable TELeheaLth Cancer CARe: The STELLAR Program to Treat Cancer Risk Behaviors
RECRUITING · NA
-
ACT Lung Health Intervention: Phase Two
RECRUITING · NA
-
Refer2Quit: Evaluating a Proactive, Tailored, Population Health Approach for Tobacco Treatment for Household Smokers Through a Pediatric Care Network
RECRUITING · NA
-
Baby Steps III: Testing a Clinician and Patient Intervention to Promote Smoking Cessation Among Pregnant Women
RECRUITING · NA
-
Urban and Reservation Implementation of All Nations Breath of Life
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00018044 · 1,000 participants
Study of Mycobacterial Infections
- NCT01036581 · 1,000 participants · NA
Advanced Functional and Structural MRI Techniques for Neuropharmacological Imaging
- NCT01192048 · 1,000 participants
Genetics of Congenital Heart Disease
- NCT01553214 · 1,000 participants · Phase 4
Improving White Blood Cell Collection From Healthy Donors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI